A clinical audit of opioid reduction in patients undergoing treatment with medicinal cannabis for chronic non-cancer pai

Not Applicable

Recruiting

• Conditions: chronic non-cancer pain; Neurological - Other neurological disorders; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12621000875808
• Lead Sponsor: Dr Philip Finch

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-06
• Last Update Posted: 12 July 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Chronic non-cancer patients referred to Perth Pain Management Centre or to Dr Michael Kent who were taking opioid medications at or after the commencement of the audit (November 2020).

Exclusion Criteria

Cannabinoid exclusion - previous significant drug addiction, pregnancy, lactation, previous psychotic illness, age (under 18) and relative exclusions of heart and liver disease.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Opioid consumption (oMEDD score - oral morphine equivalent daily dose)[Baseline, 6 months, 12 months, 18 months and 24 months post-enrolment.]

Secondary Outcome Measures

Name	Time	Method
numerical pain rating[Baseline, 6 months, 12 months, 18 months and 24 months post-enrolment];Oswestry Disability Index (ODI) [Baseline, 6 months, 12 months, 18 months and 24 months post-enrolment];insomnia severity index (ISI) [Baseline, 6 months, 12 months, 18 months and 24 months post-enrolment];depression, anxiety and stress (DASS)[Baseline, 6 months, 12 months, 18 months and 24 months post-enrolment]